| 1 |
Eslam M, Newsome PN, Sarin SK，et al.A new definition for metabolic dysfunction-associated fatty liver disease：An international expert consensus statement[J]．J Hepatol，2020，73(1)：202-209.
|
| 2 |
陈利，朱风尚，杨长青．非酒精性脂肪性肝炎相关肝细胞癌特征及诊治进展[J/OL]．中华消化病与影像杂志(电子版)，2020，10(6)：49-51.
|
| 3 |
Swislocki A．Fatty Pancreas：An Underappreciated Intersection of the Metabolic Profile and Pancreatic Adenocarcinoma[J]．Metab Syndr Relat Disord，2021，19(6)：317-324.
|
| 4 |
Shah N, Rocha JP, Bhutiani N，et al.Nonalcoholic Fatty Pancreas Disease[J]．Nutr Clin Pract，2019，34(Suppl 1)：S49-S56.
|
| 5 |
Tanaka K, Yamada S, Sonohara F，et al.Pancreatic Fat and Body Composition Measurements by Computed Tomography are Associated with Pancreatic Fistula After Pancreatectomy[J]．Ann Surg Oncol，2021，28(1)：530-538.
|
| 6 |
Guglielmi V, Sbraccia P．Type 2 diabetes：Does pancreatic fat really matter[J]．Diabetes Metab Res Rev，2018，34(2)．
|
| 7 |
Silva LLSE, Fernandes MSS, Lima EA，et al.Fatty Pancreas：Disease or Finding[J]．Clinics(Sao Paulo)，2021，76：e2439.
|
| 8 |
Dite P, Blaho M, Bojkova M，et al.Nonalcoholic Fatty Pancreas Disease：Clinical Consequences[J]．Dig Dis，2020，38(2)：143-149.
|
| 9 |
Fang T, Huang S, Chen Y，et al.Glucagon Like Peptide-1 Receptor Agonists Alters Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model[J]．Exp Clin Endocrinol Diabetes，2021，129(9)：625-633.
|
| 10 |
Ramkissoon R, Gardner TB.Pancreatic Steatosis：An Emerging Clinical Entity[J]．Am J Gastroenterol，2019，114(11)：1726-1734.
|
| 11 |
Bi Y, Wang JL, Li ML，et al.The association between pancreas steatosis and metabolic syndrome：A systematic review and meta-analysis[J]．Diabetes Metab Res Rev，2019，35(5)：e3142.
|
| 12 |
Pinte L, Balaban DV, Bǎicu C，et al.Non-alcoholic fatty pancreas disease-practices for clinicians[J]．Rom J Intern Med，2019，57(3)：209-219.
|
| 13 |
Ozturk K, Dogan T, Celikkanat S，et al.The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease[J]．Eur J Gastroenterol Hepatol，2018，30(4)：411-417.
|
| 14 |
Sakai NS, Taylor SA, Chouhan MD.Obesity，metabolic disease and the pancreas-Quantitative imaging of pancreatic fat[J]．Br J Radiol，2018，91(1089)：20180267.
|
| 15 |
Sbeit W, Greener T, Kadah A，et al.Pancreatobiliary manifestations of nonalcoholic fatty liver disease：a retrospective case-control multicenter study[J]．Eur J Gastroenterol Hepatol，2021，33(5)：722-726.
|
| 16 |
朱国英，黄东平，方青，等．脂肪肝和脂肪胰患者营养状态差异的研究[J]．同济大学学报(医学版)，2019，40(2)：213-217.
|
| 17 |
Xie J, Xu L, Pan Y，et al.Nonalcoholic fatty pancreas disease is related independently to the severity of acute pancreatitis[J]．Eur J Gastroenterol Hepatol，2019，31(8)：973-978.
|
| 18 |
Hoogenboom SA, Bolan CW, Chuprin A，et al.Pancreatic steatosis on computed tomography is an early imaging feature of pre-diagnostic pancreatic cancer：A preliminary study in overweight patients[J]．Pancreatology，2021，21(2)：428-433.
|
| 19 |
Filippatos TD, Alexakis K, Mavrikaki V，et al.Nonalcoholic Fatty Pancreas Disease：Role in Metabolic Syndrome，" Prediabetes，" Diabetes and Atherosclerosis[J]．Dig Dis Sci，2021 Jan 19.
|
| 20 |
Khoury T, Asombang AW, Berzin TM，et al.The Clinical Implications of Fatty Pancreas：A Concise Review[J]．Dig Dis Sci，2017，62(10)：2658-2667.
|
| 21 |
Gursoy Coruh A, Uzun C, Akkaya Z，et al.The relation of CT quantified pancreatic fat index with visceral adiposity and hepatic steatosis[J]．Turk J Surg，2020，36(3)：241-248.
|
| 22 |
Ahbab S, ünsal A, Ataoğlu HE，et al.Prediabetes and Type 2 Diabetes are Independent Risk Factors for Computed Tomography-Estimated Nonalcoholic Fatty Pancreas Disease[J]．Clinics(Sao Paulo)，2019，74：e1337.
|
| 23 |
Hong CW, Fazeli Dehkordy S, Hooker JC，et al.Fat Quantification in the Abdomen[J]．Top Magn Reson Imaging，2017，26(6)：221-227.
|
| 24 |
Singh RG, Yoon HD, Wu LM，et al.Ectopic fat accumulation in the pancreas and its clinical relevance：A systematic review，meta-analysis，and meta-regression[J]．Metabolism，2017，69：1-13.
|
| 25 |
Singh RG, Nguyen NN, Cervantes A，et al.Circulating levels of lipocalin-2 are associated with fatty pancreas but not fatty liver[J]．Peptides，2019，119：170117.
|
| 26 |
Romana BS, Chela H, Dailey FE，et al.Non-Alcoholic Fatty Pancreas Disease(NAFPD)：A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review[J]．Endocr Metab Immune Disord Drug Targets，2018，18(6)：547-554.
|
| 27 |
Catanzaro R, Cuffari B, Italia A，et al.Exploring the metabolic syndrome：Nonalcoholic fatty pancreas disease[J]．World J Gastroenterol，2016，22(34)：7660-7675.
|
| 28 |
Horikawa Y, Enya M, Komagata M，et al.Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome：A Case Report[J]．Diabetes Ther，2018，9(1)：421-426.
|
| 29 |
Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L，et al.Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet[J]．Pancreas，2009，38(3)：e80-e86.
|
| 30 |
Nuñez-Durán E, Chanclón B, Sütt S，et al.Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice[J]．J Endocrinol，2017，234(1)：15-27.
|
| 31 |
Gao J, Huang T, Li J，et al.Beneficial Effects of n-3 Polyunsaturated Fatty Acids on Offspring′s Pancreas of Gestational Diabetes Rats[J]．J Agric Food Chem，2019，67(48)：13269-13281.
|